Gain Therapeutics (GANX) Revenue (2020 - 2023)

Gain Therapeutics has reported Revenue for 4 years, with the latest figure at $55180.0 in Q1 2023.

• On a quarterly basis, Revenue rose 22.61% year-over-year to $55180.0 in Q1 2023; TTM through Dec 2023 was $55180.0, a 60.62% decrease from a year earlier, with the FY2023 full-year figure at $55180.0, down 60.62% from the prior year.
• Revenue was $55180.0 for Q1 2023 at Gain Therapeutics, down from $95102.0 in the prior quarter.
• The five-year high for Revenue was $95102.0 in Q2 2022, with the low at $5269.0 in Q1 2021.
• Average Revenue over 4 years is $35378.5, with a median of $27345.0 recorded in 2021.
• The largest YoY upside for Revenue was 1299.23% in 2021 against a maximum downside of 21.04% in 2021.
• Over 4 years, Revenue stood at $9139.0 in 2020, then surged by 372.79% to $43208.0 in 2021, then soared by 120.1% to $95102.0 in 2022, then sank by 41.98% to $55180.0 in 2023.
• The last three Revenue figures came in at $55180.0 (Q1 2023), $95102.0 (Q2 2022), and $45006.0 (Q1 2022), per Business Quant data.